Sign In
Buy PXMD
$0.0005
+0 (+0%)
At Close: Jun 03, 2026
ProMetic Life Sciences (OTCMKTS:PFSCF) & PaxMedica (NASDAQ:PXMD) Financial Contrast
01:14am, Tuesday, 03'rd Mar 2026
Profitability This table compares PaxMedica and ProMetic Life Sciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.
Analyzing PaxMedica (NASDAQ:PXMD) and Leap Therapeutics (NASDAQ:LPTX)
03:42am, Thursday, 18'th Dec 2025
Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and PaxMedica (NASDAQ: PXMD - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will contrast the t
BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to ann
PaxMedica Secures Immediate Exercise of Warrants
08:00am, Tuesday, 03'rd Sep 2024
TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announc
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
08:00am, Tuesday, 27'th Aug 2024
Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedi
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
08:30am, Wednesday, 15'th May 2024
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) ( OTC:PXMD ), a biopharmaceutical company dedicated to advancing treatments for
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
08:30am, Tuesday, 23'rd Apr 2024
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurolo
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
04:30pm, Tuesday, 16'th Apr 2024
TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today a
Choosing Unknown Penny Stocks, 3 Top Tips
06:39am, Monday, 15'th Apr 2024
Penny stocks represent an exciting opportunity for investors looking to expand their portfolios with potentially lucrative, yet cost-effective options. Typically trading below five dollars per share,
Why is PaxMedica (PXMD) stock surging today?
11:18am, Friday, 12'th Apr 2024
PaxMedica (NASDAQ: PXMD) has surged by 92.7% so far on Friday, reflecting the market's positive reaction to the company's announcement of significant progress in its drug development efforts.
Why Is PaxMedica (PXMD) Stock Up 93% Today?
07:51am, Friday, 12'th Apr 2024
PaxMedica (NASDAQ: PXMD ) stock is rocketing higher on Friday after the clinical-stage biopharmaceutical company reached a key milestone in drug development. The big news here is the company securing
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
04:30pm, Thursday, 11'th Apr 2024
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica , Inc. (NASDAQ: PXMD ), a biopharmaceutical company focused on advancing treatments for neurological disorders, today anno
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
08:20am, Wednesday, 13'th Mar 2024
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announ
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
08:00am, Wednesday, 06'th Dec 2023
TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Firesi
PaxMedica Announces Closing of $7.0 Million Public Offering
04:10pm, Wednesday, 22'nd Nov 2023
TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, t
